XM无法为美国居民提供服务。
B
B

Biogen

技术摘要

指标价值趋势
指标价值趋势
指标价值趋势
指标S3S2S1PR1R2R3

市场新闻

Sage to lay off more than half of R&D team, shares fall

BUZZ-Sage to lay off more than half of R&D team, shares fall ** Sage Therapeutics' shares SAGE.O fall 5.5% to $6.87 in morning trade ** Co says it will lay off more than 165 employees, including more than half of its R&D team, as part of reorganization plan ** To prioritize launch of postpartum depression pill Zurzuvae, which has been jointly devel
B
S

Sage Therapeutics' CFO to leave, drugmaker to lay off over 165 employees

UPDATE 2-Sage Therapeutics' CFO to leave, drugmaker to lay off over 165 employees Adds details on CFO leaving company in paragraphs 1, 3 and background in paragraphs 8-10 Oct 17 (Reuters) - Sage Therapeutics SAGE.O said on Thursday its finance chief will leave the company and the drugmaker plans to lay off more than 165 employees as part of a reorganization plan that aims to focus on the launch of its postpartum depression pill.
B
S

U.S. Constellation Energy, Morgan Stanley, Uber

U.S. RESEARCH ROUNDUP-Constellation Energy, Morgan Stanley, Uber Oct 17 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Constellation Energy, Morgan Stanley, and Uber, on Thursday. HIGHLIGHTS * Constellation Energy Corp CEG.O : J.P. Morgan initiates coverage with overweight rating * Illumina Inc ILMN.O : HSBC raises to buy from hold * Morgan Stanley MS.N : RBC raises target price to $122 from $108 * Uber UBER.N : Dai
A
A
A
B
B
C
C
C
G
I
S
V
U
U
G
U
W
A
A
C
C
D
D
F
F
P

Kaiser Permanente-backed biopharma CAMP4 raises $75 mln in US IPO

UPDATE 1-Kaiser Permanente-backed biopharma CAMP4 raises $75 mln in US IPO Adds background from paragraph 3 onwards Oct 10 (Reuters) - CAMP4 Therapeutics, a biopharmaceutical firm backed by healthcare giant Kaiser Permanente raised $75 million on Thursday in its U.S. initial public offering. CAMP4 sold 6.82 million shares in the IPO for $11 each, the company said in a statement.
B

Sage Therapeutics scraps Alzheimer’s drug development after trial fails; shares slide

UPDATE 3-Sage Therapeutics scraps Alzheimer’s drug development after trial fails; shares slide Adds background in paragraph 2, analyst comment in paragraph 5; updates shares Oct 8 (Reuters) - Sage Therapeutics SAGE.O said on Tuesday it would stop developing its experimental drug, dalzanemdor, for Alzheimer's disease after it failed to meet the main goal of a late-stage trial, sending its shares down 10% in premarket trading.
B
S

商品详情

热门商品

免责声明: XM Group仅提供在线交易平台的执行服务和访问权限,并允许个人查看和/或使用网站或网站所提供的内容,但无意进行任何更改或扩展,也不会更改或扩展其服务和访问权限。所有访问和使用权限,将受下列条款与条例约束:(i) 条款与条例;(ii) 风险提示;以及(iii) 完整免责声明。请注意,网站所提供的所有讯息,仅限一般资讯用途。此外,XM所有在线交易平台的内容并不构成,也不能被用于任何未经授权的金融市场交易邀约和/或邀请。金融市场交易对于您的投资资本含有重大风险。

所有在线交易平台所发布的资料,仅适用于教育/资讯类用途,不包含也不应被视为用于金融、投资税或交易相关咨询和建议,或是交易价格纪录,或是任何金融商品或非应邀途径的金融相关优惠的交易邀约或邀请。

本网站上由XM和第三方供应商所提供的所有内容,包括意见、新闻、研究、分析、价格、其他资讯和第三方网站链接,皆保持不变,并作为一般市场评论所提供,而非投资性建议。所有在线交易平台所发布的资料,仅适用于教育/资讯类用途,不包含也不应被视为适用于金融、投资税或交易相关咨询和建议,或是交易价格纪录,或是任何金融商品或非应邀途径的金融相关优惠的交易邀约或邀请。请确保您已阅读并完全理解,XM非独立投资研究提示和风险提示相关资讯,更多详情请点击 这里

风险提示: 您的资金存在风险。杠杆商品并不适合所有客户。请详细阅读我们的风险声明